PR-104 in Treating Patients With Advanced Solid Tumors

Phase 1 Completed 27 enrolled Proacta, Incorporated National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 in treating patients with advanced solid tumors.

Timeline

Start: 2005-12
Primary completion: 2007-06
Completion: 2007-06

Publications

Results Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PR104	Small molecule	135 mg/m2	Intravenous
Subject	PR104	Small molecule	1100 mg/m2	Intravenous
Subject	PR104	Small molecule	1400 mg/m2	Intravenous

PR-104 in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications